Sierra Oncology Inc (NASDAQ:SRRA) saw a large drop in short interest in the month of July. As of July 15th, there was short interest totalling 4,700 shares, a drop of 65.2% from the June 30th total of 13,500 shares. Based on an average daily volume of 27,800 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.1% of the company’s shares are sold short.
Shares of NASDAQ:SRRA opened at $11.91 on Friday. The stock has a fifty day simple moving average of $12.84 and a two-hundred day simple moving average of $11.62. Sierra Oncology has a 12-month low of $8.55 and a 12-month high of $22.00.
Sierra Oncology (NASDAQ:SRRA) last posted its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($1.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.74) by $1.43. As a group, research analysts anticipate that Sierra Oncology will post -8.15 EPS for the current year.
Several analysts have issued reports on SRRA shares. HC Wainwright initiated coverage on shares of Sierra Oncology in a research report on Thursday. They set a “buy” rating and a $20.00 price target for the company. Oppenheimer restated a “buy” rating and set a $48.00 target price on shares of Sierra Oncology in a report on Sunday, June 14th. Finally, Zacks Investment Research lowered Sierra Oncology from a “buy” rating to a “hold” rating in a research report on Friday, July 10th.
Sierra Oncology Company Profile
Sierra Oncology, Inc, a clinical stage drug development company, is advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology. Its lead drug candidate, momelotinib, is a selective and orally-bioavailable JAK1, JAK2, and ACVR1 inhibitor that has been investigated in two completed Phase 3 trials for the treatment of myelofibrosis and has demonstrated a differentiated therapeutic profile encompassing anemia-related benefits, as well as achieving substantive splenic volume reduction and constitutional symptom control.
Featured Story: What is a resistance level?
Receive News & Ratings for Sierra Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sierra Oncology and related companies with MarketBeat.com's FREE daily email newsletter.